8-KEarnings & ResultsExhibits & Filings

REGENERON PHARMACEUTICALS, INC. 8-K Report, Financial Results (Jan 13, 2015)

Filed January 13, 2015For Securities:REGN

Summary

Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 13, 2015, to report on a corporate update provided by CEO Dr. Leonard S. Schleifer at the J.P. Morgan Healthcare Conference. The primary focus of this update, and thus the key takeaway for investors from this filing, concerns the preliminary U.S. net sales figures for EYLEA® (aflibercept) Injection for the full year 2014. While specific sales numbers are not detailed within the 8-K text itself, the filing indicates that this information was presented and is available in the accompanying presentation (Exhibit 99.1). Investors interested in Regeneron's top-line performance, particularly for its flagship product EYLEA, should refer to the furnished presentation for the actual sales data and any forward-looking statements or strategic insights shared by management during the conference.

Key Highlights

  • 1Regeneron Pharmaceuticals, Inc. (REGN) filed an 8-K on January 13, 2015.
  • 2The filing provides a corporate update from CEO Dr. Leonard S. Schleifer at the J.P. Morgan Healthcare Conference.
  • 3Key information pertains to preliminary U.S. net sales for EYLEA® (aflibercept) Injection for the full year 2014.
  • 4The presentation containing these sales figures is furnished as Exhibit 99.1.
  • 5This 8-K serves to inform the market about recent company performance, specifically related to EYLEA sales.
  • 6The information is not considered 'filed' for Section 18 purposes, but is incorporated by reference in the 8-K.

Frequently Asked Questions

The main purpose of this 8-K filing is to report on a corporate update provided by Regeneron's CEO at the J.P. Morgan Healthcare Conference, specifically highlighting preliminary U.S. net sales for EYLEA® for the full year 2014.

The actual preliminary U.S. net sales figures for EYLEA® for the full year 2014 are contained within the presentation by CEO Dr. Leonard S. Schleifer, which is furnished as Exhibit 99.1 to this 8-K filing.

This 8-K filing specifically focuses on the preliminary U.S. net sales for EYLEA® Injection for the full year 2014, as presented by the CEO. It does not appear to contain broader financial results or a complete financial statement.

EYLEA® (aflibercept) Injection is a key product for Regeneron, indicated for the treatment of wet age-related macular degeneration and other serious eye diseases. Its sales performance is a critical driver of the company's revenue and profitability, making updates on its sales figures highly important for investors.